Excelsior Biopharma (6496) — Strategic Asset Allocation Index
Excelsior Biopharma (6496) has a Strategic Asset Allocation Index of 13.6% as of December 2022. Strategic assets (PP&E of NT$164.61 Million plus long-term investments of NT$-) total NT$164.61 Million, measured against net assets of NT$1.21 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Excelsior Biopharma Strategic Asset Allocation Index (2017–2022)
This chart shows how Excelsior Biopharma's Strategic Asset Allocation Index has evolved across 6 annual periods from 2017 to 2022. As of December 2022, the index stands at 13.6%, representing strategic assets of NT$164.61 Million against net assets of NT$1.21 Billion TWD. Explore 6496 cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Excelsior Biopharma (2017–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Excelsior Biopharma from 2017 to 2022, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Excelsior Biopharma.
| Year | SAAI | Strategic Assets (TWD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 13.6% | NT$164.61 Million | NT$164.61 Million | NT$- | NT$1.21 Billion | ▼ -1.7 pp |
| 2021 | 15.3% | NT$188.08 Million | NT$188.08 Million | NT$- | NT$1.23 Billion | ▼ -1.4 pp |
| 2020 | 16.7% | NT$214.31 Million | NT$214.31 Million | NT$- | NT$1.28 Billion | ▼ -0.9 pp |
| 2019 | 17.6% | NT$220.67 Million | NT$220.67 Million | NT$- | NT$1.25 Billion | ▲ +7.7 pp |
| 2018 | 9.9% | NT$135.30 Million | NT$135.30 Million | NT$- | NT$1.37 Billion | ▼ -1.3 pp |
| 2017 | 11.2% | NT$149.61 Million | NT$149.61 Million | NT$- | NT$1.34 Billion | — |